Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Work In Process (2016 - 2018)

Historic Work In Process for Theravance Biopharma (TBPH) over the last 5 years, with Q3 2018 value amounting to $3.6 million.

  • Theravance Biopharma's Work In Process rose 37989.42% to $3.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was $3.6 million, marking a year-over-year increase of 37989.42%. This contributed to the annual value of $66000.0 for FY2017, which is 9748.76% down from last year.
  • As of Q3 2018, Theravance Biopharma's Work In Process stood at $3.6 million, which was up 37989.42% from $3.3 million recorded in Q2 2018.
  • Theravance Biopharma's Work In Process' 5-year high stood at $3.6 million during Q3 2018, with a 5-year trough of $66000.0 in Q4 2017.
  • Moreover, its 4-year median value for Work In Process was $2.0 million (2018), whereas its average is $1.9 million.
  • As far as peak fluctuations go, Theravance Biopharma's Work In Process crashed by 9748.76% in 2017, and later soared by 37989.42% in 2018.
  • Theravance Biopharma's Work In Process (Quarter) stood at $145000.0 in 2014, then surged by 1711.72% to $2.6 million in 2016, then plummeted by 97.49% to $66000.0 in 2017, then soared by 5396.97% to $3.6 million in 2018.
  • Its Work In Process stands at $3.6 million for Q3 2018, versus $3.3 million for Q2 2018 and $2.0 million for Q1 2018.